Vamorolone is a new dual GR/MR ligand that has both of these properties (Heier et al., 2019) and was recently approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, after completing DMD clinical trials in which it was tested in comparison to prednisone (Hoffman et al., 2019; Mah et al., 2022; Smith et al., 2020). Here, NR3C2 is linked to Duchenne muscular dystrophy.